Alchemab Therapeutics

About

Alchemab Therapeutics is developing protective antibodies designed to keep people free of hard-to-treat diseases.

London,England,United Kingdom
11 - 50
https://alchemab.com/

Highlights

Details

Last Funding Type: Grant
Last Funding Money Raised: £1.70M
Industries: Biotechnology,Medical,Pharmaceutical
Founded date: Jan 1, 2019
Number Of Employee: 11 - 50
Operating Status: Active

Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases.

The company is building their transformative engine to identify drug targets and develop a pipeline of antibody therapeutics for hard-to-treat cancers, neurodegenerative conditions, and infectious diseases.

Alchemab Therapeutics was established in 2019 by Uri Laserson and Jane Osbourn in London, England.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

4

£61.70M $224K

Alchemab Therapeutics has raised a total of £61.70M $224K in funding over 2 rounds. Their latest funding was raised on Dec 16, 2022 from a Grant round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Dec 16, 2022	Grant	£1.70M	1	Biomedical Catalyst Fund	—	Detail
Apr 15, 2021	Series A	£60M	6	RA Capital Management	—	Detail
Jun 23, 2020	Series Unknown	$224K	—	—	—	Detail
Dec 1, 2019	Seed	—	1	DCVC Bio	—	Detail

Investors

Number of Lead Investors

Number of Investors

3

8

Alchemab Therapeutics is funded by 8 investors. Biomedical Catalyst Fund and RA Capital Management are the most recent investors.

Investor Name	Lead Investor	Funding Round
Biomedical Catalyst Fund	Yes	Grant
RA Capital Management	Yes	Series A
DCVC Bio	Yes	Seed
DCVC	—	Series A
Dementia Discovery Fund	—	Series A
DHVC	—	Series A
Lightstone Ventures	—	Series A
SV Health Investors	—	Series A